Navigation Links
Amarin Provides 2010 Year-End Review to Shareholders
Date:1/31/2011

d under a Special Protocol Assessment agreement (SPA) with the U.S. Food and Drug Administration (FDA). In contrast to previous studies of omega-3 fatty acids and fibrate treatments of patients with very high triglyceride levels, AMR101 is the first such triglyceride-lowering therapy demonstrated to reduce triglycerides without significantly increasing LDL-cholesterol levels. We expect to present the full data set at an upcoming medical conference this year.

Completed Patient Randomization for ANCHOR Trial Ahead of Schedule with Top-Line Results Expected in Q2 2011The ANCHOR trial, a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study, evaluates the efficacy and safety of 2 grams and 4 grams of AMR101 in patients with high triglyceride levels (200 mg/dL to less than 500 mg/dL) who are also on statin therapy. Patients in this trial are characterized as having high triglyceride levels with mixed dyslipidemia (two or more lipid disorders) and are at high risk for the development of cardiovascular disease. Currently, no omega-3 based therapy is approved by the FDA for treating this patient population. The treatment of high triglyceride levels represents a major commercial opportunity as first-in-class prescription medicine, as an estimated 36 million patients in the U.S. alone have high triglycerides. The primary endpoint in this trial is triglyceride reduction from baseline compared to placebo. This trial is being conducted under an SPA agreement with the FDA.

Strengthened Amarin's Senior Management and Board of DirectorsA year ago, we were shifting our operational focus to our Research and Development Headquarters in the U.S., becoming solely focused on cardiovascular opportunities, and launching our Phase 3 trials.  The team as constituted for this mission completed the MARINE trial earlier than initially expected and we believe is poised to do the same with the ANCHOR trial. The team at Amarin, together with it
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin to Present at UBS Life Sciences Conference
4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
6. Amarin Prices Public Offering of American Depositary Shares
7. Amarin Announces Underwriters Exercise of Over-Allotment Option
8. Amarin Announces Successful Completion of Offering of American Depositary Shares
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Results of the recent study, ... MarginProbe for Intra-Operative Positive Margin Detection , were presented ... 32 nd Annual Miami Breast Cancer Conference last ... Moshe Papa , MD, FACS, Professor of Surgery at ... reports an analysis of MarginProbe,s efficiency and accuracy when ...
(Date:3/4/2015)... --Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted ... announced that James A. Joyce , Aethlon Medical ... the 27th Annual ROTH Conference on March 10, 2015 ... California . To learn more about the ROTH ... live webcast of the presentation will be available on ...
(Date:3/4/2015)... , March 4, 2015  Kannalife Sciences, Inc. ("Kannalife") ... joined its Scientific Advisory Board to assist the Company ... towards the use of cannabinoid therapeutics for the treatment ... forensic pathologist responsible for conducting the full autopsy of ... Fame center for the Pittsburgh Steelers. It was through ...
Breaking Medicine Technology:New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2Aethlon Medical to Present at the 27th Annual ROTH Conference 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3
... SPARTANBURG, S.C., Aug. 16, 2011 Femasys Inc. and ... distribution rights in the United States as well as ... Device. This FDA cleared device is used to evaluate ... Sono HSG. Femasys Inc. is an emerging medical device ...
... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), ... system, today announced that it has filed its Form 10-Q ... U.S. Securities and Exchange Commission. The Company provided an update ... Year-to-date shipment volumes increased 93% compared to ...
Cached Medicine Technology:Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis 2InspireMD Provides Mid-Year Strategic Update 2InspireMD Provides Mid-Year Strategic Update 3InspireMD Provides Mid-Year Strategic Update 4InspireMD Provides Mid-Year Strategic Update 5InspireMD Provides Mid-Year Strategic Update 6InspireMD Provides Mid-Year Strategic Update 7
(Date:3/4/2015)... Plungerhead has partnered with the Boot ... after their service to the country. The new partnership, ... social media and several national special events, as well ... special retail promotion of Plungerhead Lodi Zinfandel and Plungerhead ... , “There is a vital need and responsibility ...
(Date:3/4/2015)... Port Richey, FL (PRWEB) March 04, 2015 ... Medical Detox cut the ribbon on their new facility in ... Pasco Chamber of Commerce. The new facility will allow the ... of helping end the prescription drug abuse epidemic through treatment ... current reality of drug addiction in the United States, we ...
(Date:3/4/2015)... The Conrad N. Hilton Foundation has awarded ... million, which will help 151,000 people access safe, clean ... The programs cover three years and the investment will ... water points in disrepair, addressing water quality ... water points and ensuring safe water supplies for the ...
(Date:3/4/2015)... Problem Gambling Awareness Month (PGAM) is here, ... organizations across the nation in this grassroots public awareness ... policymakers, and others about problem gambling as a public ... and FCCG partner organizations are calling upon the medical ... gambling problem, to make treatment readily available, and to ...
(Date:3/4/2015)... Jose, California (PRWEB) March 04, 2015 ... CNS therapeutics market is driven by the increasing incidence ... an encouraging pipeline of late stage drugs. The unmet ... to fore the untapped potential in the market. Presently, ... effective drugs that overcome the limitations of current generation ...
Breaking Medicine News(10 mins):Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 2Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 2Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 3Health News:Hilton Foundation Gives $6.9 Million to Sustainable Water Programs in West Africa 4Health News:Problem Gambling - A Public Health Issue; March Is Problem Gambling Awareness Month 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 4
... and TUDCA were found to restore healthy glucose levels and ... new research.// The study is published in the August 25 ... Harvard School of Public Health (HSPH). ,Type 2 ... - affects an estimated 18 million people in the United ...
... in the body has been identified by researchers from ... the fiber// physically tears epithelial cells thereby releasing the ... biologist at the Medical College of Georgia and corresponding ... scheduled for the September print issue of PloS Biology ...
... for terminal patients is better when they avoid hospital care.// ... hospice care are almost half as likely to spend the ... than residents who are not in hospice care. ... data from around 184,000 nursing home residents in five states. ...
... of California, San Diego (UCSD) School of Medicine, along ... Lima, Peru, have// developed a novel approach for assessing ... severe, water-borne disease that is the common cause of ... areas throughout the developing world – from environmental water ...
... the proposed discount drug plan, which will entail about ... ones for the// low-income residents of the state. ... companies to enable discounts. All companies will be required ... they may stand to be removed from Medi-Cal's preferred ...
... knows it better than US health experts who have set ... virulence// of an allergic reaction called anaphylaxis. ... with such alacrity, affecting many parts of the body. Food, ... the cause of nearly 1,500 deaths in the United States. ...
Cached Medicine News:Health News:Two Chemical Compounds Restore Healthy Glucose Levels In Obese Mice 2Health News:Two Chemical Compounds Restore Healthy Glucose Levels In Obese Mice 3Health News:What does High-fiber Foods Really do? 2Health News:New Approach Assesses Risk of Water-Borne Pathogen Disease 2Health News:New Approach Assesses Risk of Water-Borne Pathogen Disease 3
LB Agar plates with 0.1mM EDTA....
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth...
Medicine Products: